MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, discovered in 2015 by researchers at the USC Leonard Davis School of Gerontology. Preclinical studies show it improves insulin sensitivity, enhances fat oxidation, and boosts physical performance with effects similar to exercise. The…
One of the most studied areas of MOTS-c involves its effects on metabolism. In a 2015 study, mice fed a high-fat diet and treated with MOTS-c gained significantly less weight and demonstrated improved insulin sensitivity compared to untreated controls 1 . A 2019 metabolomics analysis further revealed that MOTS-c enhances beta-oxidation, the process by which fatty acids are broken down for energy. At the same time, the peptide lowered activity in three metabolic pathways that are typically elevated in obesity: sphingolipid metabolism, monoacylglycerol metabolism, and dicarboxylate metabolism 4 .
Human observational data also support these findings. A 2018 study published in Pediatric Diabetes measured circulating MOTS-c levels in obese male children and adolescents. The researchers found that these individuals had much lower MOTS-c levels compared to their lean counterparts. Lower MOTS-c levels showed a negative correlation with body mass index, fasting insulin levels, and HOMA-IR, a measure of insulin resistance 3 . This suggests that reduced MOTS-c may be linked to metabolic dysfunction and obesity.
MOTS-c is classified as an exercise-induced peptide, meaning it is naturally released during physical activity. It joins other peptides in this category such as CJC-1295, Ipamorelin, and BPC-157. A 2021 study published in Nature Communications examined the effects of MOTS-c on physical capacity. In humans, skeletal muscle levels of MOTS-c rose during exercise. In mice, exogenous administration of MOTS-c boosted physical performance across all age groups. Notably, mice receiving late-life treatment at 23.5 months of age still achieved measurable gains in running endurance and grip strength 2 .
The study highlights the peptide's potential to mimic some metabolic effects of exercise, even in older or sedentary individuals. This has drawn significant interest for aging and performance research.
Metabolic stress can arise from various sources, including exercise, illness, chronic disease, or trauma. Under such conditions, MOTS-c appears to play a protective role. Within 30 minutes of metabolic stress, the peptide translocates from the mitochondria to the cell nucleus 5 . Once in the nucleus, it activates NRF2-dependent antioxidant gene expression, helping to combat oxidative damage. This is the first known example of a mitochondrial-encoded peptide directly regulating nuclear genes in this manner 5 . The ability to respond quickly to stress may help maintain cellular health and resilience.
Published safety data for MOTS-c itself remain very limited. A Phase 1a/1b clinical trial tested CB4211, an analog of MOTS-c, rather than the native peptide. That trial enrolled 65 healthy adults and 20 obese individuals with non-alcoholic fatty liver disease NAFLD . No serious adverse events were reported; the only side effects were minor injection site discomfort, which is common with any injectable compound. However, the study did not involve MOTS-c directly, and no formal toxicology study for MOTS-c exists in the peer-reviewed literature 1 2 4 . While the benefits observed in preclinical models appear to come without obvious downsides, human safety data are still needed.
MOTS-c exerts its effects primarily through activation of AMPK, the cell's master energy sensor. It does so by inhibiting the folate cycle and boosting accumulation of AICAR, a natural AMPK activator 1 . This two-pronged mechanism leads to several downstream effects: insulin-independent glucose uptake, enhanced fatty acid oxidation, and stimulation of mitochondrial biogenesis 1 4 . Under conditions of metabolic stress, the peptide also switches on antioxidant defense genes through the NRF2 pathway 5 . This dual action on both energy metabolism and stress protection makes MOTS-c a subject of intense research interest.
In preclinical studies, MOTS-c has been administered via intraperitoneal injection. Doses have ranged from 5 to 15 mg per kilogram of body weight in mouse models 1 2 . Protocols varied between studies. Lee and colleagues in 2015 used a sustained dosing schedule combined with a high-fat diet intervention. Reynolds and colleagues in 2021 examined both daily and intermittent schedules, with the intermittent group receiving injections three times per week 1 2 . A standardized human research protocol has not yet been established in peer-reviewed literature, leaving room for further investigation.
In Canada, MOTS-c is not classified as a controlled substance, so researchers can purchase it without a prescription or special regulatory approvals. Polar Peptides, a domestic manufacturer, offers MOTS-c at 99 percent purity, backed by third-party high-performance liquid chromatography and mass spectrometry testing. The company also supplies other research peptides such as NAD+, AOD 9604, and GHK-Cu peptide. Polar Peptides markets itself as the only Canadian manufacturer capable of providing MOTS-c at that purity level with independent lab verification.
What does MOTS-c do in the body?
It activates AMPK by inhibiting the folate cycle and increasing AICAR accumulation. This leads to insulin-independent glucose uptake, better fatty acid oxidation, and mitochondrial biogenesis. Under stress, it also activates NRF2-dependent antioxidant genes 1 4 5 .
How does MOTS-c make a person feel?
Research suggests that MOTS-c can improve physical performance, including strength and stamina, and may enhance fat oxidation. However, it is not necessarily something that produces an immediate subjective feeling 2 .
How long does it take for MOTS-c to work?
The timeline depends on the outcome measured. The peptide can reach the nucleus within 30 minutes of metabolic stress to provide protective effects 5 . Physical performance gains and changes in body weight may take weeks of administration 2 .
Are there any known side effects?
No side effects have been reported in the available studies, but this does not mean none exist. The safety profile has not been fully characterized in peer-reviewed research. The CB4211 Phase 1 trial and multiple preclinical studies across different labs and dosing protocols provide some reassurance 1 2 4 .
Is it legal to buy MOTS-c online in Canada?
Yes. MOTS-c is not a controlled substance, so it can be purchased for research purposes without a prescription. Polar Peptides is a supplier in Canada.
It is encoded in mitochondrial DNA rather than nuclear DNA, and it is the only known peptide that translocates from mitochondria to the nucleus to regulate gene expression directly 5 .
Can MOTS-c be used for weight loss?
Preclinical data suggest it may prevent obesity, improve insulin sensitivity, and enhance fat oxidation 1 4 . Human studies also show that lower circulating MOTS-c levels are associated with higher BMI and insulin resistance 3 .
The research discussed in this article is supported by multiple peer-reviewed studies:
1. Lee C, Zeng J, Drew BG, et al. "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance." Cell Metabolism. 2015;21 3 :443-454. https://pubmed.ncbi.nlm.nih.gov/25738459/
2. Reynolds JC, Lai RW, Woodhead JST, et al. "MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis." Nature Communications. 2021;12:470. https://pubmed.ncbi.nlm.nih.gov/33473109/
3. Du C, Zhang C, Wu W, et al. "Circulating MOTS-c Levels Are Decreased in Obese Male Children and Adolescents and Associated With Insulin Resistance." Pediatric Diabetes. 2018;19 6 :1058-1064. https://pubmed.ncbi.nlm.nih.gov/29691953/
4. Kim SJ, Miller B, Mehta HH, et al. "The Mitochondrial-Derived Peptide MOTS-c Is a Regulator of Plasma Metabolites and Enhances Insulin Sensitivity." Physiological Reports. 2019;7 13 :e14171. https://pubmed.ncbi.nlm.nih.gov/31293078/
5. Kim KH, Son JM, Benayoun BA, Lee C. "The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress." Cell Metabolism. 2018;28 3 :516-524. https://pubmed.ncbi.nlm.nih.gov/29983246/
6. Fuku N, Pareja-Galeano H, Zempo H, et al. "The Mitochondrial-Derived Peptide MOTS-c: A Player in Exceptional Longevity?" Aging Cell. 2015;14 6 :921-923. https://pubmed.ncbi.nlm.nih.gov/26289118/
Peptides referenced: BPC-157, Ipamorelin, CJC-1295, GHK-Cu, MOTS-c, Copper Tripeptide-1, AICAR.
Vendors referenced: Polar Peptides.
Related reading: BPC-157 and TB-500 Benefits: Resilience and Repair Explained, KLOW vs GLOW Peptide Stacks: Key Differences and Research Roles, Combination Gene Therapy and GLP-1 Drug Repairs Heart Damage in Mice, QuickFire Challenge for Oral Peptide Delivery Announced.